Prospect for enzyme therapy in glycogenosis II variants: a study on cultured muscle cells
- PMID: 3065462
- DOI: 10.1007/BF00314479
Prospect for enzyme therapy in glycogenosis II variants: a study on cultured muscle cells
Abstract
Impairment of skeletal muscle function is the common feature of distinct clinical forms of glycogenosis type II. In the present study, muscle cultures from different patients were used to investigate the cause of clinical heterogeneity and the feasibility of enzyme replacement therapy. The activity of acid alpha-glucosidase appears to be the primary factor in determining the extent of lysosomal glycogen storage in muscle, and thereby the clinical severity of the disease. Neutral alpha-glucosidases do not seem influential. Correction of the enzymatic defect was achieved in skeletal muscle cultures from patients by administration of a "high-uptake" form of acid alpha-glucosidase, purified from human urine. The enzyme reaches the lysosomes, including the glycogen storage vacuoles, and the lysosomal glycogen content is reduced to control level. In normal muscle cells 20% of the total cellular glycogen pool is segregated in lysosomal compartments. This percentage is higher than in fibroblasts, which may partly explain why muscles are more prone to store glycogen. The relevance of this study for enzyme therapy is discussed.
Similar articles
-
Receptor-mediated uptake of acid alpha-glucosidase corrects lysosomal glycogen storage in cultured skeletal muscle.Pediatr Res. 1988 Jul;24(1):90-4. doi: 10.1203/00006450-198807000-00021. Pediatr Res. 1988. PMID: 2970619
-
Bovine generalised glycogenosis type II. Uptake of lysosomal alpha-glucosidase by cultured skeletal muscle and reversal of glycogen accumulation.FEBS Lett. 1985 Oct 14;190(2):301-4. doi: 10.1016/0014-5793(85)81305-3. FEBS Lett. 1985. PMID: 3899727
-
Bovine glycogenosis type II. Biochemical and morphological characteristics of skeletal muscle in culture.Neuropathol Appl Neurobiol. 1984 Sep-Oct;10(5):379-95. doi: 10.1111/j.1365-2990.1984.tb00368.x. Neuropathol Appl Neurobiol. 1984. PMID: 6395034
-
Pompe disease (glycogen storage disease type II): clinical features and enzyme replacement therapy.Acta Neurol Belg. 2006 Jun;106(2):82-6. Acta Neurol Belg. 2006. PMID: 16898258 Review.
-
Diagnosis of glycogenosis type II.Neurology. 2008 Dec 2;71(23 Suppl 2):S4-11. doi: 10.1212/WNL.0b013e31818da91e. Neurology. 2008. PMID: 19047572 Review.
Cited by
-
Production of a functional human acid maltase in tobacco seeds: biochemical analysis, uptake by human GSDII cells, and in vivo studies in GAA knockout mice.Appl Biochem Biotechnol. 2013 Oct;171(4):916-26. doi: 10.1007/s12010-013-0367-z. Epub 2013 Aug 2. Appl Biochem Biotechnol. 2013. PMID: 23907679 Free PMC article.
-
Glycogen storage disease type IIa.Indian J Pediatr. 1996 Mar-Apr;63(2):259-62. doi: 10.1007/BF02845254. Indian J Pediatr. 1996. PMID: 10829999 No abstract available.
-
High-level production of recombinant human lysosomal acid alpha-glucosidase in Chinese hamster ovary cells which targets to heart muscle and corrects glycogen accumulation in fibroblasts from patients with Pompe disease.Proc Natl Acad Sci U S A. 1996 Jan 9;93(1):65-70. doi: 10.1073/pnas.93.1.65. Proc Natl Acad Sci U S A. 1996. PMID: 8552676 Free PMC article.
-
Glycogenosis type II: protein and DNA analysis in five South African families from various ethnic origins.Am J Hum Genet. 1989 Jun;44(6):787-93. Am J Hum Genet. 1989. PMID: 2658562 Free PMC article.
-
Adult and infantile glycogenosis type II in one family, explained by allelic diversity.Am J Hum Genet. 1990 Jan;46(1):45-52. Am J Hum Genet. 1990. PMID: 2403755 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources